<template>
	<div class="grid grid-cols-1 grid-rows-1 pb-6 relative z-10 h-full">
		<div class="page-content flex flex-col justify-end font-effra pr-14">
			<div>
				<the-h1 class="text-electric-blue">
					EXBLIFEP<span class="font-extrabold">®</span> is where microbiological eradication* meets efficacy<sup
						class="text-[50%] font-extrabold -top-[0.8em]"
						>1</sup
					>
				</the-h1>
				<img
					src="/lime-green-border.png"
					alt="Lime Green Border"
					class="h-1.5 w-[240px] my-2.5"
				/>
			</div>
			<section class="grid grid-cols-2 mt-5 bg-white py-6 px-8 text-cool-grey gap-y-9 gap-x-16 max-w-[860px]">
				<div class="flex gap-x-3.5 items-center col-span-2">
					<img
						src="/summary-icon-1.png"
						alt="Summary Icon 1"
						class="w-[85px] h-[85px]"
					/>
					<div class="min-w-[3px] h-[44px] bg-electric-blue"></div>
					<the-body-lg>
						EXBLIFEP® is indicated for the
						<span class="text-dark-blue font-bold"
							>treatment of adult patients with cUTI including pyelonephritis, HAP/VAP and bacteraemia associated with these infections,</span
						>
						caused by gram-negative bacteria<sup class="text-[65%] -top-[0.6em] font-medium">5</sup>
					</the-body-lg>
				</div>
				<div class="flex gap-x-3.5 items-center">
					<img
						src="/summary-icon-2.png"
						alt="Summary Icon 2"
						class="w-[85px] h-[85px]"
					/>
					<div class="min-w-[3px] h-[44px] bg-electric-blue"></div>
					<the-body-lg class="min-w-[290px]">
						EXBLIFEP® demonstrated
						<span class="text-dark-blue font-bold">non-inferiority and superiority vs piperacillin/tazobactam</span> in the composite endpoint of
						clinical cure and microbiological eradication in adults with cUTIs at Day 14 in the Primary Analysis Set?<sup
							class="text-[65%] -top-[0.6em] font-medium"
							>†1</sup
						>
					</the-body-lg>
				</div>
				<div class="flex gap-x-3.5 items-center">
					<img
						src="/summary-icon-3.png"
						alt="Summary Icon 3"
						class="w-[85px] h-[85px]"
					/>
					<div class="min-w-[3px] h-[44px] bg-electric-blue"></div>
					<the-body-lg>
						EXBLIFEP® is indicated to treat HAP/VAP, and
						<span class="text-dark-blue font-bold"
							>could be a useful carbapenem-<br />sparing option for ESBL Class A-<br />producing pathogens<sup
								class="text-[65%] -top-[0.6em] font-extrabold"
								>5,10</sup
							></span
						>
					</the-body-lg>
				</div>
				<div class="flex gap-x-3.5 items-center">
					<img
						src="/summary-icon-4.png"
						alt="Summary Icon 4"
						class="w-[85px] h-[85px]"
					/>
					<div class="min-w-[3px] h-[44px] bg-electric-blue"></div>
					<the-body-lg class="min-w-[285px]">
						EXBLIFEP® demonstrated <span class="text-dark-blue font-bold">high intrapulmonary penetration</span> and similar distribution kinetics
						of both compounds into the ELF, supporting its use in the treatment of HAP/VAP<sup class="text-[65%] -top-[0.6em] font-medium">6,9</sup>
					</the-body-lg>
				</div>
				<div class="flex gap-x-3.5 items-center">
					<img
						src="/summary-icon-5.png"
						alt="Summary Icon 5"
						class="w-[85px] h-[85px]"
					/>
					<div class="min-w-[3px] h-[44px] bg-electric-blue"></div>
					<the-body-lg>
						EXBLIFEP® demonstrated a
						<span class="text-dark-blue font-bold">favourable overall safety profile, comparable to</span>
						piperacillin tazobactam<sup class="text-[65%] -top-[0.6em] font-medium">1,9</sup>
					</the-body-lg>
				</div>
			</section>

			<section class="max-w-[1380px] bg-[#00EAFF] shadow-dark py-[7px] flex items-center mt-7 relative z-10 border-[3px] border-white">
				<div class="pl-[22px] pr-4 py-[7px] border-r-[3px] border-[#002470]">
					<svg
						xmlns="http://www.w3.org/2000/svg"
						width="40"
						height="40"
						viewBox="0 0 40 40"
						fill="none"
					>
						<g clip-path="url(#clip0_387_22384)">
							<path
								d="M0.828125 0.522461L16.7684 20.2623L0.828125 40.0021H9.68382L25.6241 20.2623L21.1962 14.7838L9.68382 0.522461H0.828125Z"
								fill="#002470"
							/>
							<path
								d="M14.4785 0.293945L30.4188 20.0338L14.4785 39.7674H23.3342L39.2745 20.0338L34.8466 14.5491L23.3342 0.293945H14.4785Z"
								fill="#002470"
							/>
						</g>
						<defs>
							<clipPath id="clip0_387_22384">
								<rect
									width="38.4474"
									height="39.7082"
									fill="white"
									transform="translate(0.828125 0.293945)"
								/>
							</clipPath>
						</defs>
					</svg>
				</div>
				<h2 class="pl-6 text-[14px] leading-tight max-h-[28px] font-bold text-[#002470] max-w-[1200px]">
					At ADVANZ PHARMA, we are committed to taking your treatment options further to improve patient lives,<br />
					by providing novel therapeutic options in the fight against gram-negative and gram-positive infections
				</h2>
			</section>
		</div>
		<footer class="flex flex-col mt-10">
			<the-footnotes class="footer max-w-[1380px] font-effra text-cool-grey max-h-[84px]">
				AMR, antimicrobial resistance; AP, acute pyelonephritis; CFU, colony-forming unit; cUTI, complicated urinary tract infection; ELF, epithelial
				lining fluid; HAP/VAP, hospital-acquired pneumonia/ventilator<br />
				associated pneumonia; MIC, minimum inhibitory concentration.<br />
				*In the ALLIUM study, microbiological eradication is defined as &lt;10<sup>3</sup> CFU/mL of qualifying baseline pathogen in urine.<sup>1</sup
				><br />
				<sup>†</sup>Primary outcome was the proportion of patients in the primary analysis set (PAS) who achieved a composite outcome of complete
				resolution of the baseline signs and symptoms present at screening<br />
				(clinical cure) and reduction of qualifying baseline pathogen to less than 10<sup>3</sup> CFU/mL in urine (microbiological eradication) at Day
				14. The PAS included all patients who received at least 1 dose of study<br />
				drug and had a gram-negative baseline pathogen in urine at 10<sup>5</sup> CFU/mL or more or the same pathogen present in both blood and urine
				cultures that was not resistant to either cefepime/<br />enmetazobactam (MIC ≤8 μg/mL) or piperacillin/tazobactam (MIC ≤64 μg/mL).<sup>1</sup>
			</the-footnotes>
			<div class="flex justify-end items-center mt-3.5 mr-12">
				<explore-another-short />
			</div>
		</footer>
	</div>
</template>

<script setup>
import { toRef } from 'vue';

import { usePageAnimation } from '@/composables/usePageAnimation.js';

import ExploreAnotherShort from '@/components/ExploreAnotherShort.vue';

import TheH1 from '@/components/exblifep/TheH1.vue';
import TheBodyLg from '@/components/exblifep/TheBodyLg.vue';
import TheFootnotes from '@/components/exblifep/TheFootnotes.vue';

const props = defineProps({
	sidebarOpen: {
		type: Boolean,
		required: true,
	},
});

const sidebarOpenRef = toRef(props, 'sidebarOpen');
usePageAnimation(sidebarOpenRef);
</script>
